HF
PTLA

HRT Financial’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

HRT Financial’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7,656
Closed -$205K – 1871
2019
Q3 		$205K Buy
+7,656
New +$215K 0.01% 1143

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

HRT Financial's PTLA Position: Q4 2019 in Review

HRT Financial sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2019, closing a stake of 7,656 shares — an estimated $205K sold.

HRT Financial first reported a position in PTLA in Q3 2019 and held it in 1 quarter. The position peaked at $205K in Q3 2019. 224 funds tracked by Wall St. Rank hold PTLA as of Q4 2019.

  • HRT Financial reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • HRT Financial sold 7,656 Portola Pharmaceuticals, Inc. shares in Q4 2019, an estimated $205K.
  • HRT Financial first reported a position in Portola Pharmaceuticals, Inc. in Q3 2019 and held it in 1 quarter.
  • HRT Financial's Portola Pharmaceuticals, Inc. position peaked at $205K in Q3 2019.
  • 224 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2019.

Based on HRT Financial's 13F filing for Q4 2019, filed 14 Feb 2020.